
Genialis Supermodel Forecasts Patient Response to HER2-Targeted Therapy Enhertu
Genialis Supermodel Predicts Patient Response to HER2-Targeted Therapy Enhertu Genialis, the therapeutic intelligence company, announced it will present the first results from a new AI-based algorithm designed to distinguish between patients more likely to benefit from treatment with trastuzumab deruxtecan (Enhertu®, T-DXd).…











